ACE Technology Guidances

ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 01 Apr 2022
Last Updated on 12 Jul 2022
A- A+
Guidance Recommendations

The Ministry of Health's Drug Advisory Committee has not recommended aflibercept, bevacizumab reference biologic (Avastin) or ramucirumab for subsidy for treating metastatic colorectal cancer.

Bevacizumab (Avastin) has not been recommended in view of unfavourable cost effectiveness compared with bevacizumab biosimilar (Mvasi) at the price proposed by the manufacturer.

Aflibercept has not been recommended due to low clinical need and unfavourable cost effectiveness compared with Mvasi.

Ramucirumab has not been recommended following a request from the manufacturer to not consider it for subsidy.

Clinical indications, subsidy class and MediShield Life claim limits for all drugs included in the evaluation are provided in the Annex.


PES Treatments for metastatic colorectal cancer (Updated 19 December 2022) Aflibercept, bevacizumab and ramucirumab for treating metastatic colorectal cancer (12 Jul 22)